Project Grant K25CA317042
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $192K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $2.46 million Project Grant on August 18, 2025, under the Cancer Treatment Research program (CFDA 93.395) to support the INHANCE (Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery) initiative. This five-year project, extending through July 31, 2030, focuses on developing advanced imaging and computational image analysis methodologies to predict, detect,...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The University of Texas MD Anderson Cancer Center a $1,098,702 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2026, through August 31, 2030. This initiative, titled "Preclinical and Clinical Digital Twins of ES and DSRCT: A Joint Initiative Between Academia, Pharma and Patient Advocates to Model Investigational Agents and Prioritize Them for Clinical...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $680,129 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports the development of drug-loaded degradable biopolymeric scaffolds designed to augment preoperative liver growth in patients with hepatic tumors. The project addresses critical clinical needs in hepatic resection by creating a sustained-delivery system...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $421,685 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period June 1, 2026 through May 31, 2028. The award funds the development of advanced statistical methodologies to improve risk assessment for rare cancer patients at individual medical institutions by leveraging information from external source cohorts. The project addresses a critical...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $621,632 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 17, 2026, with a completion date of May 31, 2031. The award supports research to elucidate the mechanisms underlying disulfidptosis—a previously unexplored form of regulated cell death—and to develop therapeutic strategies targeting this cell death pathway in SLC7A11-high cancers. The...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 2, 2025, with completion scheduled for June 30, 2027. This award supports research aimed at developing targeted therapeutic approaches for E-cadherin-negative diffuse-type gastric adenocarcinoma (DGAC), an aggressive cancer subtype with increasing incidence rates and poor...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $226,884 Project Grant under the Cancer Research Manpower program (CFDA 93.398) effective December 18, 2025, with completion scheduled for June 2, 2028. This award supports biomedical training and workforce development in cancer research aligned with the National Cancer Program, enabling MD Anderson to provide educational and research training opportunities for...
- Federal Grant Award Summary The National Cancer Institute awarded MD Anderson Cancer Center a $706,739 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, for research spanning through May 31, 2031. This award supports research to unravel the molecular mechanisms of immunotherapy-associated myocarditis, a severe cardiac inflammation condition that occurs as a toxicity of immune checkpoint inhibitor (ICI) treatments used in cancer therapy. The research will...